Voltron Therapeutics
Voltron Therapeutics is dedicated to advancing immunotherapy through its revolutionary platform that precisely targets tumors and pathogens, engaging multiple components of the immune system to identify, target, and kill specific diseases. Founded in 2017, it holds an exclusive worldwide license to its technology, which has shown promising results in pre-clinical studies for infectious diseases and oncology. The company's mission is to deliver novel, highly efficacious treatments for cancers and infectious diseases, aiming to improve patient outcomes with faster, safer, and more flexible solutions.
Industries
Nr. of Employees
small (1-50)
Voltron Therapeutics
Products
Modular self-assembling vaccine platform
A modular prophylactic and therapeutic vaccine platform that pairs a consistent immune-activating protein backbone with interchangeable antigenic attachments to generate targeted cellular immunity for oncology and infectious disease indications.
Modular self-assembling vaccine platform
A modular prophylactic and therapeutic vaccine platform that pairs a consistent immune-activating protein backbone with interchangeable antigenic attachments to generate targeted cellular immunity for oncology and infectious disease indications.
Services
Sponsored preclinical research collaborations
Research partnerships and sponsored research agreements with academic centers to design and execute preclinical immuno-oncology and infectious disease studies.
Joint-development and licensing collaborations
Formation of joint ventures and licensing arrangements to co-develop platform applications and specific vaccine candidates.
Sponsored preclinical research collaborations
Research partnerships and sponsored research agreements with academic centers to design and execute preclinical immuno-oncology and infectious disease studies.
Joint-development and licensing collaborations
Formation of joint ventures and licensing arrangements to co-develop platform applications and specific vaccine candidates.
Expertise Areas
- Vaccine platform development
- Immuno-oncology preclinical development
- Preclinical immunogenicity and efficacy testing
- Biologics CMC and scale-up
Key Technologies
- Self-assembling modular vaccine architecture
- HSP70-based protein immune adjuvant backbone
- Biotin–avidin style modular conjugation
- CHO cell line biologics production